유빅스테라퓨틱스
Seoul, KR · 20 known investors
Ubix Therapeutics (주식회사 유빅스테라퓨틱스) is a South Korean company whose services include a health-management offering that processes health data such as blood oxygen saturation, blood glucose, blood pressure, heart rate, height, and weight. The page reviewed is a privacy policy and gives limited detail about the company's core business.
Also known as (주)유빅스테라퓨틱스 · Ubix Therapeutics · 유빅스 · 주식회사 유빅스테라퓨틱스
Investors · 20
Also in the syndicate · 18
Company profile
researched Aug 2026Ubix Therapeutics (㈜유빅스테라퓨틱스) is a Seoul-based biotechnology company that develops oncology drug candidates using targeted protein degradation (TPD). Its core platform, Degraducer®, uses bifunctional small molecules that link a ligand binding a disease-related target protein to a binder for an E3 ubiquitin ligase, recruiting the target into the cell's ubiquitin-proteasome system for degradation. The company positions the approach as a way to address targets considered undruggable by conventional inhibitors and to overcome resistance to existing drugs. Registered business activity is medical and pharmaceutical research and development.
The pipeline is led by UBX-303-1, an oral BTK degrader in development for B-cell lymphoma, which received US FDA Phase 1 IND clearance in December 2023, Korean Phase 1 IND approval in September 2024, and conditional Phase 1 IND approval in Poland in January 2025, with first patient dosing beginning in February 2025. UBX-103 (YH45057), an AR degrader for prostate cancer, was derived as a candidate in March 2023 and licensed to Yuhan Corporation in July 2024; company records list the termination of that agreement in October 2025. A further candidate, UBX-106, was selected in May 2025. As of December 2024 the company reported eight TPD oncology programs. Supporting platform elements UbiCore and UbiDesign were completed in December 2023.
The company operates from the Munjeong Hyundai Knowledge Industry Center in Songpa-gu, Seoul, following earlier locations in Gangnam-gu and the Seoul Bio Hub in Dongdaemun-gu, and maintains a bio research laboratory in Seoul and a synthetic chemistry laboratory in Incheon. Corporate data providers report 37-39 employees, paid-in capital of KRW 5.49 billion and 2025 revenue of KRW 1.07 billion against an operating loss of KRW 10.49 billion.
Founding story
Ubix Therapeutics was established in June 2018 by Seo Bo-kwang, who serves as CEO. According to a Korean-language encyclopedia entry, he studied microbiology (BSc) and immunology (MSc) at Seoul National University and previously worked at JW Pharmaceutical, Genexine, SK Telecom's in-vitro diagnostics business unit and the bio-focused investment firm Lifecore Partners before founding the company. In July 2018 the company licensed in BRD4 and EED4 degrader technology and a novel CRBN binder from the Korea Research Institute of Chemical Technology and the Korea Research Institute of Bioscience and Biotechnology, forming the basis of the Degraducer® platform.
Business model
The company is a pre-commercial drug developer that funds itself with venture capital and public R&D grants and monetises its Degraducer® platform through licensing and collaborative research agreements with pharmaceutical companies, typically involving upfront payments, milestones and options on candidate compounds. Reported revenue is small relative to operating losses (KRW 1.07 billion revenue and a KRW 10.49 billion operating loss in 2025), consistent with revenue arising from partnership and licensing income rather than product sales.
Revenue derives from out-licensing and co-development agreements on platform-derived candidates. The July 2024 license of UBX-103 to Yuhan Corporation was reported at a total of KRW 150 billion including a KRW 5 billion upfront payment; the agreement is recorded as terminated in October 2025. Other agreements with SK Biopharmaceuticals and Debiopharm include technology-transfer options on resulting candidates.
Traction
As of December 2024 the company reported eight TPD oncology programmes and cumulative investment of KRW 63 billion. Lead asset UBX-303-1 obtained Phase 1 IND clearances in the United States (December 2023), Korea (September 2024) and Poland (conditional, January 2025), with first patient dosing in February 2025, and was selected for a Korea Drug Development Fund clinical development project in October 2025. UBX-103 was out-licensed to Yuhan in July 2024 (agreement terminated October 2025). Research results were published in Blood Advances in November 2022. Awards include a Ministry of Health and Welfare minister's citation (November 2021) and an IR52 Jang Young-shil Technology Innovation Award (November 2022). Financially, revenue was KRW 5.15 billion in 2024 and KRW 1.07 billion in 2025, with operating losses of KRW 6.62 billion and KRW 10.49 billion respectively.
Latest developments
In March 2026 the company voluntarily withdrew its KOSDAQ preliminary listing review, indicating it would re-attempt a listing after clinical results and technology transfers became clearer. During 2025 it began patient dosing in the UBX-303-1 Phase 1 trial (February), signed a Degrader-Antibody Conjugate co-development agreement with Y-Biologics (February), selected the UBX-106 candidate (May), signed a material transfer agreement with Fore US Bio for UBX-106 development (July), had UBX-303-1 selected for a Korea Drug Development Fund clinical development project (October), and recorded the termination of the Yuhan UBX-103 licence (October).
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
Ubix Therapeutics is one of several Korean companies working in targeted protein degradation and is described in trade press as a TPD-focused drug discovery biotech. Its pre-IPO round was characterised by the company as an oversubscribed raise reflecting evaluation of the Degraducer® platform, and it obtained A/A technology-evaluation grades from EcreditBle and Korea Enterprise Data in 2025, qualifying it to file for a KOSDAQ preliminary listing review. A jobs-portal ranking places it 209th of 211 companies in its pharmaceutical/bio industry grouping by disclosed revenue, reflecting its pre-commercial stage.
The company's stated differentiators are proprietary and licensed-in E3 ligase binders (including a patented novel CRBN binder), platform component technologies UbiCore and UbiDesign, and an ability to combine degrader payloads with antibody and linker technologies to create degrader-antibody conjugates. It emphasises degradation of undruggable targets and overcoming resistance to existing inhibitors, together with academic collaborations providing high-throughput screening (POSTECH), structural biology (Gachon University) and in-silico screening and modelling (Kyungpook National University).
Technology
Degraducer® is a targeted protein degradation platform built on bifunctional small molecules: a ligand that binds the disease-associated target protein is joined by a linker to a binder for an E3 ubiquitin ligase, bringing the target into proximity with the ligase so that it is ubiquitinated and degraded by the proteasome (the ubiquitin-proteasome system). The company states this allows targeting of proteins not addressable by conventional inhibitors and can overcome acquired drug resistance. Novel E3 ligase binders, including a CRBN binder, were licensed from Korean government research institutes, and platform component technologies named UbiCore and UbiDesign were completed in December 2023. The company also develops Degrader-Antibody Conjugates (also described as Antibody-Degraducer Conjugates, ADeC) by combining Degraducer® payloads with partner linker and antibody technologies.
Go-to-market
The company advances candidates from discovery through early clinical development in-house and then seeks licensing or co-development agreements with larger pharmaceutical partners, who take over later-stage development and commercialisation. It also participates in Korean government-funded R&D programmes (Korea Drug Development Fund non-clinical and clinical projects, Ministry of SMEs and Startups scale-up TIPS and Super Gap Startup programmes) and joined J&J JLABS as a member company in October 2024.
Pharmaceutical and biotechnology companies that license or co-develop degrader candidates, with cancer patients — initially B-cell lymphoma and prostate cancer populations — as the eventual therapeutic end users.
Geography
Headquartered in Songpa-gu, Seoul, South Korea, with a bio research laboratory in Seoul and a synthetic chemistry laboratory in Incheon. Clinical development spans Korea, the United States and Poland, and partners include Switzerland-based Debiopharm and US-based Fore US Bio and NeoImmuneTech.
History
Founded in June 2018 in Gangnam-gu, Seoul, the company raised angel funding of KRW 1.78 billion in September 2018 and closed a KRW 4 billion Series A in January 2019. It established its in-house research institute in 2019, with a bio laboratory in Seoul and a synthesis laboratory in Incheon, and registered a patent on a novel CRBN binder in October 2019. A Series B of KRW 15 billion closed in April 2020 and a Series C (reported as KRW 12 billion or KRW 14 billion depending on the source) in March 2023. Partnerships followed with NeoImmuneTech (2020), Debiopharm (2021), SK Biopharmaceuticals (2022), Y-Biologics (2025) and Fore US Bio (2025). A pre-IPO round of KRW 25.7 billion closed in December 2024, bringing cumulative investment to KRW 63 billion. The company passed technology evaluation with A/A grades in August 2025 and filed for a KOSDAQ listing, then withdrew the preliminary listing review in March 2026, stating it would reapply after clinical results and technology transfers became more visible.
Risks & controversies
The company is loss-making, with a 2025 operating loss of KRW 10.49 billion and a net loss of KRW 15.14 billion, and 2025 revenue fell about 79% year on year. Its UBX-103 licence with Yuhan Corporation, signed in July 2024, is recorded as terminated in October 2025. Its KOSDAQ listing attempt was withdrawn at the preliminary review stage in March 2026. Industry-ranking data places it near the bottom of its peer grouping on revenue-based measures of profitability and growth.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 25
launches, deals, and filingsThe company withdrew its KOSDAQ preliminary listing application, stating it would reapply once clinical results and technology transfers become more visible.
Received A grades from evaluation agencies EcreditBle and Korea Enterprise Data, obtaining eligibility to file a KOSDAQ preliminary listing review.
Company announced completion of a pre-IPO round of KRW 25.7 billion, exceeding an initial KRW 20 billion target, bringing cumulative investment to KRW 63 billion; proceeds earmarked for US and Korean clinical development of UBX-303-1, pipeline expansion and commercialisation.
Global exclusive licence to Yuhan Corporation for development and commercialisation of the prostate cancer AR degrader UBX-103 (YH45057), reported at a total value of KRW 150 billion including a KRW 5 billion upfront payment; Yuhan was to lead clinical trial preparation.
Phase 1 investigational new drug application for the oral BTK degrader UBX-303-1 approved by the US FDA.
Co-research and development agreement applying the Degraducer® TPD platform to discover cancer drugs including immuno-oncology agents, with SK Biopharmaceuticals able to secure exclusive development rights to resulting candidates.
Joint research and technology-transfer option agreement with Switzerland-based Debiopharm combining Degraducer® with Debiopharm's Multilink™ antibody-drug conjugate linker technology to create Antibody-Degraducer Conjugates (ADeC).
Agreement granting NeoImmuneTech an exclusive licence to develop up to three drug candidates using the Degraducer® platform.
Signed technology in-licensing agreements with the Korea Research Institute of Chemical Technology and the Korea Research Institute of Bioscience and Biotechnology for BRD4 and EED4 degraders and for a novel CRBN binder used in the Degraducer® platform.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- 유빅스테라퓨틱스ubixtrx.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does 유빅스테라퓨틱스 do?
- South Korean biotech developing targeted protein degradation cancer drugs on its Degraducer® platform.
- Who are 유빅스테라퓨틱스's investors?
- 유빅스테라퓨틱스's investors include Atinum Investment Co. Ltd., Solidus Investment.
- Where is 유빅스테라퓨틱스 headquartered?
- 유빅스테라퓨틱스 is headquartered in Seoul, KR.